-
Mashup Score: 84
Renowned radiation oncologist Felix Y. Feng, MD, passed away from cancer on Dec. 10, 2024, at the age of 48.
Source: www.ucsf.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Oncology Center of Excellence - 11 day(s) ago
About the Oncology Center of Excellence
Source: www.fda.govCategories: General Medicine News, UrologyTweet-
JUST IN: new @US_FDA warnings about 5-FU, a drug approved in 1962!. This re: patients with dihydropyrimidine dehydrogenase (DPD) deficiency. https://t.co/LrEHrDQxVY
-
-
Mashup Score: 5
While the announcement is good news for the Princess of Wales, cancer experts describe the challenges of a life shadowed by an earlier diagnosis.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/bHkwx1gMb3 via @nytimes with comments from our own @DanaFarber @KimmieNgMD !
-
-
Mashup Score: 5
While the announcement is good news for the Princess of Wales, cancer experts describe the challenges of a life shadowed by an earlier diagnosis.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/bHkwx1gMb3 via @nytimes with comments from our own @DanaFarber @KimmieNgMD !
-
-
Mashup Score: 54Looking Back, Looking Forward | A KidneyCAN Town Hall - 16 day(s) ago
Renowned kidney cancer researchers share a retrospective of 2024 breakthroughs, along with a look forward at 2025.
Source: kidneycan.orgCategories: General Medicine News, Hem/OncsTweet-
Kidney cancer Powerhouses @AlbigesL and @montypal hosted by @kidneycan for a special seminar on the latest research in Kidney cancer--Can't miss this one! LINK: https://t.co/YnOcVEmlKR @advocatekidneys @brian_rini @KidneyCancerDoc @tompowles1 @GustaveRoussy @cityofhope… https://t.co/DUQ6oOU3ma https://t.co/2zo1PZTdm0
-
-
Mashup Score: 27Home - 17 day(s) ago
With novel radiopharmaceutical therapies entering clinical trials and into clinical practice, the 2025 Transatlantic Exchange in Oncology will focus on bringing together key experts from Boston, USA and Paris, France to highlight the latest advances in the application of these targeted agents for oncology. The 1-day event will deliver a comprehensive overview of this highly competitive and dynamic area within the R & D landscape, enabling attendees to understand cutting-edge research as well as the
Source: events.medscapelive.orgCategories: General Medicine News, Hem/OncsTweet-
Don’t miss this one ! 4th “exchanges “ between @DanaFarber & @GustaveRoussy —this time around “Radioligand Therapies”, with the help of @Servier support and @Medscape for logistics--March 25th in beautiful Paris! Free registration: https://t.co/QVGtkOJ1F6 @OncoAlert… https://t.co/zKuK5N7Hjk https://t.co/awv8Niwd82
-
-
Mashup Score: 10
Belzutifan plus cabozantinib has promising antitumour activity in patients with pretreated clear cell renal cell carcinoma and our findings provide rationale for further randomised trials with belzutifan in combination with a VEGFR tyrosine-kinase inhibitor.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
4/ Our findings from previously treated patients were reported separately, also in @lancetOncol https://t.co/C4X3H8InRg https://t.co/pdK7KwoXBw
-
-
Mashup Score: 21
Jennifer Chan, MD, MPH – Medical Oncology
Source: www.dana-farber.orgCategories: General Medicine News, Hem/OncsTweet-
Paper 5: Encouraging results from the phase 3 #CABINET trial in @NEJM : #cabozantinib ⬆️ PFS in previously treated, advanced extrapancreatic or pancreatic #NET by our own Dr Jen Chan (https://t.co/516GHNlNIv) at @DanaFarber https://t.co/YMfuGM7zct https://t.co/ntN8zqemcM
-
-
Mashup Score: 82
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
The @US_FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors —-Agonistic approval ! @DanaFarber_GU @OncoAlert @ASCO https://t.co/vO1e808f2J
-
-
Mashup Score: 37Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | NEJM - 1 month(s) ago
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive uro…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
7/ AMBASSADOR Trial: In patients with MIBC, adjuvant pembrolizumab resulted in DFS benefit (Median DFS 29.6 vs 14.2 months) over observation @apolo_andrea @NEJM https://t.co/rT2U8akKU6 https://t.co/2MaTS1kBKm
-
Felix Feng, Giant in the Field of Prostate Cancer, Dies at 48 | @UCSF We miss you Felix. We promise to honor your legacy. We love you Felix. @mishabeltran @DrPaulNguyen @JoshLangMD @nlinmd #EricSmall https://t.co/k14o0QUpix